Cognitive Effects of Statin Medications
详细信息 查看全文
- 作者：Brendan J. Kelley (1)
Stephen Glasser (2) - 刊名：CNS Drugs
- 出版年：2014
- 出版时间：May 2014
- 年：2014
- 卷：28
- 期：5
- 页码：411-419
- 全文大小：
- 参考文献：1. US Food and Drug Administration. FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs; 2012 (cited 9 July 2013). http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm293330.htm
2. Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy. 2001;21(6):767-. CrossRef
3. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003;23(7):871-0. CrossRef
4. Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy. 2009;29(7):800-1. CrossRef
5. Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer’s disease. Neuroepidemiology. 2004;23(1-):94-. CrossRef
6. Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry. 2005;62(2):217-4. CrossRef
7. Zhou B, Teramukai S, Fukushima M. Prevention and treatment of dementia or Alzheimer’s disease by statins: a meta-analysis. Dement Geriatr Cogn Disord. 2007;23(3):194-01. CrossRef
8. Beydoun MA, Beason-Held LL, Kitner-Triolo MH, Beydoun HA, Ferrucci L, Resnick SM, et al. Statins and serum cholesterol’s associations with incident dementia and mild cognitive impairment. J Epidemiol Community Health. 2011;65(11):949-7. CrossRef
9. Bettermann K, Arnold AM, Williamson J, Rapp S, Sink K, Toole JF, et al. Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study. J Stroke Cerebrovasc Dis. 2011;21(6):436-4.
10. Benito-Leon J, Louis ED, Vega S, Bermejo-Pareja F. Statins and cognitive functioning in the elderly: a population-based study. J Alzheimers Dis. 2010;21(1):95-02.
11. Parker BA, Polk DM, Rabdiya V, Meda SA, Karen Anderson RN, Hawkins KA, et al. Changes in memory function and neuronal activation associated with atorvastatin therapy. Pharmacotherapy. 2010;30(6):236e-0e. CrossRef
12. King DS, Wilburn AJ, Wofford MR, Harrell TK, Lindley BJ, Jones DW. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy. 2003;23(12):1663-. CrossRef
13. Glasser SP, Wadley V, Judd S, Kana B, Prince V, Jenny N, et al. The association of statin use and statin type and cognitive performance: analysis of the reasons for geographic and racial differences in stroke (REGARDS) study. Clin Cardiol. 2010;33(5):280-. CrossRef
14. Harrison RW, Ashton CH. Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br J Clin Pharmacol. 1994;37(3):231-. CrossRef
15. Peters JT, Garwood CL, Lepczyk M. Behavioral changes with paranoia in an elderly woman taking atorvastatin. Am J Geriatr Pharmacother. 2008;6(1):28-2. CrossRef
16. Caballero J, Nahata M. Do statins slow down Alzheimer’s disease? A review. J Clin Pharm Ther. 2004;29(3):209-3. CrossRef
17. Ivnik RJ, Smith GE, Petersen RC, Boeve BF, Kokmen E, Tangalos EG. Diagnostic accuracy of four approaches to interpreting neuropsychological test data. Neuropsychology. 2000;14(2):163-7. CrossRef
18. Chen P, Ratcliff G, Belle SH, Cauley JA, DeKosky ST, Ganguli M. Patterns of cognitive decline in presymptomatic Alzheimer disease: a prospective community study. Arch Gen Psychiatry. 2001;58(9):853-. CrossRef
19. Chen P, Ratcliff G, Belle SH, Cauley JA, DeKosky ST, Ganguli M. Cognitive tests that best discriminate between presymptomatic AD and those who remain nondemented. Neurology. 2000;55(12):1847-3. CrossRef
20. Terrera GM, Matthews F, Brayne C. A comparison of parametric models for the investigation of the shape of cognitive change in the older population. BMC Neurol. 2008;8:16. CrossRef
21. Duff K, Beglinger LJ, Moser DJ, Paulsen JS, Schultz SK, Arndt S. Predicting cognitive change in older adults: the relative contribution of practice effects. Arch Clin Neuropsychol. 2010;25(2):81-. CrossRef
22. Frerichs RJ, Tuokko HA. A comparison of methods for measuring cognitive change in older adults. Arch Clin Neuropsychol. 2005;20(3):321-3. CrossRef
23. Temkin NR, Heaton RK, Grant I, Dikmen SS. Detecting significant change in neuropsychological test performance: a comparison of four models. J Int Neuropsychol Soc. 1999;5(4):357-9. CrossRef
24. Heaton RK, Temkin N, Dikmen S, Avitable N, Taylor MJ, Marcotte TD, et al. Detecting change: a comparison of three neuropsychological methods, using normal and clinical samples. Arch Clin Neuropsychol. 2001;16(1):75-1. CrossRef
25. Callahan CM, Unverzagt FW, Hui SL, Perkins AJ, Hendrie HC. Six-item screener to identify cognitive impairment among potential subjects for clinical research. Med Care. 2002;40(9):771-1. CrossRef
26. Wang TJ, Stafford RS, Ausiello JC, Chaisson CE. Randomized clinical trials and recent patterns in the use of statins. Am Heart J. 2001;141(6):957-3. CrossRef
27. Anderson TJ, Gregoire J, Hegele RA, Couture P, Mancini GB, McPherson R, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2012;29(2):151-7. CrossRef
28. Armitage J. The safety of statins in clinical practice. Lancet. 2007;370(9601):1781-0. CrossRef
29. Naidu A, Xu Q, Catalano R, Cordell B. Secretion of apolipoprotein E by brain glia requires protein prenylation and is suppressed by statins. Brain Res. 2002;958(1):100-1. CrossRef
30. Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke. 1999;30(9):1969-3. CrossRef
31. Kostis JB, Rosen RC, Wilson AC. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. J Clin Pharmacol. 1994;34(10):989-6. CrossRef
32. Gengo F, Cwudzinski D, Kinkel P, Block G, Stauffer L, Lines C. Effects of treatment with lovastatin and pravastatin on daytime cognitive performance. Clin Cardiol. 1995;18(4):209-4. CrossRef
33. Cutler N, Sramek J, Veroff A, Block G, Stauffer L, Lines C. Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia. Br J Clin Pharmacol. 1995;39(3):333-. CrossRef
34. Gibellato MG, Moore JL, Selby K, Bower EA. Effects of lovastatin and pravastatin on cognitive function in military aircrew. Aviat Space Environ Med. 2001;72(9):805-2.
35. Trompet S, van Vliet P, de Craen AJ, Jolles J, Buckley BM, Murphy MB, et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol. 2010;257(1):85-0. CrossRef
36. Berk-Planken I, de Konig I, Stolk R, Jansen H, Hoogerbrugge N. Atorvastatin, diabetic dyslipidemia, and cognitive functioning. Diabetes Care. 2002;25(7):1250-. CrossRef
37. Parale GP, Baheti NN, Kulkarni PM, Panchal NV. Effects of atorvastatin on higher functions. Eur J Clin Pharmacol. 2006;62(4):259-5. CrossRef
38. Summers MJ, Oliver KR, Coombes JS, Fassett RG. Effect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial. Pharmacotherapy. 2007;27(2):183-0. CrossRef
39. Golomb BA, Criqui MH, White HL, Dimsdale JE. The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes. Control Clin Trials. 2004;25(2):178-02. CrossRef
40. Golomb BA, Dimsdale JE, White HL, Ritchie JB, Criqui MH. Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial. Arch Intern Med. 2008;168(7):721-. CrossRef
41. Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med. 2004;117(11):823-. CrossRef
42. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-2. CrossRef
43. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623-0. CrossRef
44. Hajjar I, Schumpert J, Hirth V, Wieland D, Eleazer GP. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci. 2002;57(7):M414-. CrossRef
45. Etminan M, Gill S, Samii A. The role of lipid-lowering drugs in cognitive function: a meta-analysis of observational studies. Pharmacotherapy. 2003;23(6):726-0. CrossRef
46. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry. 2009;80(1):13-. CrossRef
47. Hyttinen L, TuulioHenriksson A, Vuorio AF, Kuosmanen N, Harkanen T, Koskinen S, et al. Long-term statin therapy is associated with better episodic memory in aged familial hypercholesterolemia patients in comparison with population controls. J Alzheimers Dis. 2010;21(2):611-.
48. Steenland K, Zhao L, Goldstein FC, Levey AI. Statins and cognitive decline in older adults with normal cognition or mild cognitive impairment. J Am Geriatr Soc. 2013;61:1449-5. CrossRef
49. Rosenberg PB, Mielke MM, Tschanz J, Cook L, Corcoran C, Hayden KM, et al. Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. Am J Geriatr Psychiatry. 2008;16(11):883-2. CrossRef
50. Arvanitakis Z, Schneider JA, Wilson RS, Bienias JL, Kelly JF, Evans DA, et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology. 2008;70(19 Pt 2):1795-02.
51. Bernick C, Katz R, Smith NL, Rapp S, Bhadelia R, Carlson M, et al. Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology. 2005;65(9):1388-4. CrossRef
52. Rockwood K, Howlett S, Fisk J, Darvesh S, Tuokko H, Hogan DB, et al. Lipid-lowering agents and the risk of cognitive impairment that does not meet criteria for dementia, in relation to apolipoprotein E status. Neuroepidemiology. 2007;29(3-):201-. CrossRef
53. Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology. 2008;71(5):344-0. CrossRef
54. Ancelin ML, Carriere I, Barberger-Gateau P, Auriacombe S, Rouaud O, Fourlanos S, et al. Lipid lowering agents, cognitive decline, and dementia: the three-city study. J Alzheimers Dis. 2012;30(3):629-7.
55. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97(8A):52C-0C. CrossRef
56. Algotsson A, Winblad B. Patients with Alzheimer’s disease may be particularly susceptible to adverse effects of statins. Dement Geriatr Cogn Disord. 2004;17(3):109-6. CrossRef
57. Padala KP, Padala PR, Potter JF. Simvastatin-induced decline in cognition. Ann Pharmacother. 2006;40(10):1880-. CrossRef
58. Galatti L, Polimeni G, Salvo F, Romani M, Sessa A, Spina E. Short-term memory loss associated with rosuvastatin. Pharmacotherapy. 2006;26(8):1190-. CrossRef
59. Stuart SA, Robertson JD, Marrion NV, Robinson ES. Chronic pravastatin but not atorvastatin treatment impairs cognitive function in two rodent models of learning and memory. PLoS ONE. 2013;8(9):e75467. CrossRef
60. Scott HD, Laake K. Statins for the reduction of risk of Alzheimer’s disease. Cochrane Database Syst Rev. 2001(3):CD003160.
61. Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer’s disease: current status and new perspectives. Lancet Neurol. 2003;2(9):539-7. CrossRef
62. Petanceska SS, DeRosa S, Olm V, Diaz N, Sharma A, Thomas-Bryant T, et al. Statin therapy for Alzheimer’s disease: will it work? J Mol Neurosci. 2002;19(1):155-1.
63. Hoglund K, Thelen KM, Syversen S, Sjogren M, von Bergmann K, Wallin A, et al. The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2005;19(5-):256-5.
64. Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Lopez J, Browne P. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer’s disease: results of the Alzheimer’s Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol Scand Suppl. 2006;185:3-. CrossRef
65. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010;74(12):956-4. CrossRef
66. Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 2011;77(6):556-3. CrossRef
67. McGuinness B, O’Hare J, Craig D, Bullock R, Malouf R, Passmore P. Cochrane review on ‘Statins for the treatment of dementia- Int J Geriatr Psychiatry. 2012;28(2):119-6.
68. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8(6):373-18. CrossRef
69. Hannah-Shmouni F, Al-Sarraf A, Frohlich J, Mezei MM, Sirrs S, Mattman A. Safety of statin therapy in patients with mitochondrial diseases. J Clin Lipidol. 2013;7(2):182. CrossRef
70. Vladutiu GD, Simmons Z, Isackson PJ, Tarnopolsky M, Peltier WL, Barboi AC, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve. 2006;34(2):153-2. CrossRef
71. Dong W, Vuletic S, Albers JJ. Differential effects of simvastatin and pravastatin on expression of Alzheimer’s disease-related genes in human astrocytes and neuronal cells. J Lipid Res. 2009;50(10):2095-02. CrossRef
72. Brandes RP. Statin-mediated inhibition of Rho: only to get more NO? Circ Res. 2005;96(9):927-. CrossRef
73. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res. 2005;97(12):1232-. CrossRef
74. Rex CS, Chen LY, Sharma A, Liu J, Babayan AH, Gall CM, et al. Different Rho GTPase-dependent signaling pathways initiate sequential steps in the consolidation of long-term potentiation. J Cell Biol. 2009;186(1):85-7. CrossRef
75. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev. 2009(2):CD003160.
76. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006;112(1):71-05. CrossRef
77. White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol. 2002;42(9):963-0. CrossRef
78. Joshi HN, Fakes MG, Serajuddin ATM. Differentiation of 3-hydroxy-3methylglutary-coenzyme A reductase inhibitors by their relative lipophilicity. Pharm Pharmacol Commun. 1999;5:269-1. CrossRef
79. Vaughan CJ, Gotto AM Jr. Update on statins: 2003. Circulation. 2004;110(7):886-2. CrossRef - 作者单位：Brendan J. Kelley (1)
Stephen Glasser (2)
1. Department of Neurology, The Ohio State University, Columbus, OH, 43210, USA
2. Division of Preventive Medicine and Department of Epidemiology, University of Alabama at Birmingham, Birmingham, USA - ISSN：1179-1934
文摘
The demonstrated benefits of 3-hydroxy-3-methylglutaryl coenzyme?A (HMG-CoA) reductase inhibitors (statins) for cardiovascular and cerebrovascular disease are well established in the medical literature, and this class of medications is among those most commonly prescribed in the USA. In 2012, the US Food and Drug Administration issued updated recommendations regarding statin medications, and the panel’s comments regarding memory impairment fostered clinical confusion (in part because of the lay media’s amplification). Cognitive data from several large epidemiological studies have not reliably demonstrated a robust association between incident cognitive impairment and statin use, with some studies reporting a protective effect, some reporting an increased risk and others finding no association. Although several interventional studies have evaluated statins as a possible adjunctive treatment for Alzheimer’s disease, none have clearly demonstrated a benefit. A small number of case series have reported infrequent memory difficulties associated with statin use. In these series, the patients-cognitive symptoms resolved after statin discontinuation. The existing medical literature does not suggest that cognitive considerations should play a major role in medical decision making to prescribe statins for the large majority of patients. As with any medication prescribed for older adults, careful clinical monitoring for side effects should be exercised. If a patient is suspected of having idiosyncratic memory impairment associated with use of a statin medication, the drug can be discontinued. The patient should then be followed with careful clinical observation for 1-?months for resolution of the cognitive symptoms.